Ignite Creation Date:
2024-05-06 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 2:23 PM
Study NCT ID:
NCT05218499
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-22
First Post:
2022-01-18
Brief Title:
Brightline-1 A Study to Compare Brigimadlin BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Organization Data
Organization:
Boehringer Ingelheim
Class:
INDUSTRY
Study ID:
1403-0008
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Boehringer Ingelheim
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None